Finanzen von Biohaven Ltd. (BHVN)BHVNBiohaven Ltd.

Evaluating the bottom line, Biohaven Ltd. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -799.46%, provide a clear picture of how effectively BHVN converts its operational activities into shareholder value.

In the context of the broader market, BHVN competes directly with industry leaders such as PAHC and BRVE. With a market capitalization of $2.10B, it holds a leading position in the sector. When comparing efficiency, BHVN's gross margin of N/A stands against PAHC's 31.73% and BRVE's N/A. Such benchmarking helps identify whether Biohaven Ltd. is trading at a premium or discount relative to its financial performance.

Biohaven's financial performance shows a concerning trend with negative net income projected for upcoming quarters, including -$130.53 million in Q1 2026 and -$137.31 million in Q2 2026. The current ratio is strong at 7.41, indicating good short-term financial health, but the debt to equity ratio has surged to 2123.06%, raising concerns about leverage.